» Articles » PMID: 15151718

In-vitro Maturation of Immature Oocytes for Infertile Women with PCOS

Overview
Publisher Elsevier
Date 2004 May 21
PMID 15151718
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Immature oocyte retrieval followed by in-vitro maturation (IVM) is a promising potential treatment option, especially for women who are infertile through polycystic ovarian syndrome (PCOS). Although the pregnancy and implantation rates of IVM treatment are not as high as conventional IVF treatment, IVM treatment has many advantages for infertile women with PCOS, because this group of patients is extremely sensitive to stimulation with exogenous gonadotrophins and is at increased risk of developing ovarian hyperstimulation syndrome (OHSS). Different protocols have been used before immature oocyte retrieval, indicating that there are beneficial effects with FSH or LH priming on oocyte maturation. To date, the clinical pregnancy and implantation rates obtained from IVM treatment in infertile women with PCOS are approximately 30-35% and 10-15% respectively. Therefore, as an option, IVM treatment can be offered to women with PCOS instead of conventional IVF treatment with ovarian stimulation.

Citing Articles

Success in Parenthood: The In Vitro Maturation Breakthrough in Infertility.

Choudhary N, Shrivastava J, More A, Anjankar A, Shrivastava D Cureus. 2024; 16(4):e57486.

PMID: 38707084 PMC: 11066372. DOI: 10.7759/cureus.57486.


IVM of human immature oocytes for infertility treatment and fertility preservation.

Chian R, Li J, Lim J, Yoshida H Reprod Med Biol. 2023; 22(1):e12524.

PMID: 37441160 PMC: 10335168. DOI: 10.1002/rmb2.12524.


Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility.

Costello M, Misso M, Balen A, Boyle J, Devoto L, Garad R Hum Reprod Open. 2019; 2019(1):hoy021.

PMID: 31486807 PMC: 6396642. DOI: 10.1093/hropen/hoy021.


Could fertility clinics offer a sizable improvement of live birth rates by maturing post-GVBD oocytes in vitro?.

Martin-Palomino Olid N, Garcia D, Rodriguez A, Vassena R J Assist Reprod Genet. 2019; 36(9):1927-1934.

PMID: 31376102 PMC: 6730726. DOI: 10.1007/s10815-019-01540-8.


Comparison of GnRH agonist and hCG for priming in vitro maturation cycles in cancer patients undergoing urgent fertility preservation.

El Hachem H, Sonigo C, Benard J, Presse M, Sifer C, Sermondade N PLoS One. 2018; 13(12):e0208576.

PMID: 30521621 PMC: 6283534. DOI: 10.1371/journal.pone.0208576.